Nadine Rouphael

Learn More
BACKGROUND Avian influenza A/H5N1 has threatened human health for nearly 2 decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for mass vaccination will be needed if a pandemic occurs. METHODS A multicenter, randomized, blinded phase 1 clinical trial evaluated safety and antibody responses after point-of-use(More)
Antibody responses and cytokines induced by Meningococcal vaccines. (a) ELISPOT captured day 7 IgG antibody-secreting cells (ASCs) in a subset of vaccinees. Plates were coated with goat anti human IgG antibody, MCV4, DT or MPSV4 and detected with anti human IgG biotin and streptavidin HRP. (b) Two representative subjects are shown. On the left, 1X(More)
Human herpesviruses are important causes of potentially severe chronic infections for which T cells are believed to be necessary for control. In order to examine the role of virus-specific CD8 T cells against Varicella Zoster Virus (VZV), we generated a comprehensive panel of potential epitopes predicted in silico and screened for T cell responses in(More)
Background.  We report the first-in-human safety and immunogenicity evaluation of a highly attenuated, replication-competent recombinant vesicular stomatitis virus (rVSV) human immunodeficiency virus (HIV)-1 vaccine. Methods.  Sixty healthy, HIV-1-uninfected adults were enrolled in a randomized, double-blinded, placebo-controlled dose-escalation study.(More)
Background.  Mortality for cryptococcal meningitis remains significant, in spite of available treatment. Resistance to first-line maintenance therapy, particularly fluconazole, has been reported. Methods.  A retrospective chart review was performed on immunocompromised patients with cryptococcal meningitis, who had susceptibility testing performed between(More)
Users may view, print, copy, download and text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: prepared online data portal and Figure 3a. C.D. did experiments in Supplementary Figure 1a, b. S.K. assisted with experiments in Figure 6 and Supplementary Figure 16. M.J.M.(More)
  • 1